Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jun 7, 2021- First-of-its-kind steerable delivery system designed for left atrial appendage (LAA) occluder to seal the LAA in people who are at increased risk of stroke due to atrial fibrillation- New delivery system works with Abbott's leading Amplatzer Amulet™ LAA Occluder device to enable better access to the LAA and seals off a broad range of LAA anatomies- Steerable sheath gives physicians enhanced flexibility and precise placement when implanting Amplatzer Amulet
-
Jun 7, 2021- All 16 Walgreens locations in the city of Philadelphia will provide the rapid BinaxNOW™ COVID-19 Antigen Self Test at no cost to customers who present a Pennsylvania EBT ACCESS Card, starting June 7 and running through July 4- First-of-its-kind pilot program aims to increase consumer access to rapid testing- BinaxNOW is the most studied and widely available rapid antigen test in the U.S. and has been available nationwide for over-the-counter (OTC), non-prescription purchase at Walgreens since mid-April
- Jun 3, 2021- Abbott has the capacity and supply to support increased demand for mechanical circulatory support (MCS) devices following Medtronic's decision to stop the global distribution and sale of the Medtronic HeartWare™ ventricular assist device (HVAD)- Access to MCS devices are critical for advanced heart failure patients and can improve survival, clinical outcomes and quality of life- Abbott is working with physicians and health systems to ensure supply of left ventricular assist devices (LVADs) alongside training and education for implanting physicians now offering Abbott's HeartMate 3™ to their patients
- Jun 1, 2021- Updated outlook reflects lower recent and projected demand for COVID-19 tests- Revised forecast continues to reflect strong, double-digit EPS growth on both a GAAP and adjusted basis- Abbott's base business, excluding COVID-19 testing-related sales, continues to achieve strong growth- R&D pipeline continues to be highly productive, with a steady cadence of recent and upcoming product launches across the portfolio
-
May 18, 2021Addressing High Blood Pressure to Reduce Health Disparities in Central Texas Underserved Communities- American Heart Association and Abbott announce new initiative to advance health equity, fight high blood pressure and chronic conditions in greater Austin area
- May 17, 2021- Latest-generation TAVI system features advancements to reduce or eliminate risk of blood leakage around valve implant- The non-surgical Navitor TAVI system offers best-in-class deliverability and access through small vessels, expanding treatment options for patients with severe aortic stenosis
-
May 12, 2021- Newly issued guidance from the U.S. Centers for Disease Control and Prevention now accepts rapid, self-administered testing option that meet its criteria- United customers can depart the U.S. with the Abbott BinaxNOW™ Home Test in their carry-on bag and administer the test via the eMed digital health platform to re-enter the U.S.
- May 6, 2021- A new, first-of-its-kind study known as TAP-CHF leverages expertise across Abbott's cardiovascular portfolio to optimize treatment for patients suffering from both AFib and heart failure- The trial will utilize Abbott technology including cardiac ablation and sensors to monitor for both pulmonary artery pressure and abnormal heartbeats- Historically, treating patients with both AFib and heart failure has been challenging, with few effective treatments or options to adequately manage both conditions simultaneously
-
Apr 26, 2021- New imaging platform merges optical coherence tomography (OCT) with the power of automation using artificial intelligence (AI)- Ultreon 1.0 Software helps physicians automatically detect and quantify blood vessel characteristics, giving them better insights for optimal patient treatment- Platform offers advanced imaging features when combined with the Dragonfly OpStar™ imaging catheter used to access complex anatomy
- Apr 20, 2021- Sales growth of 35.3 percent; organic sales growth of 32.9 percent- GAAP diluted EPS growth from continuing operations of 233.3 percent; adjusted diluted EPS growth of 103.1 percent- All four major businesses achieved strong sales growth in the quarter- Projected full-year EPS remains unchanged; reflects growth of more than 35 percent
-
Apr 19, 2021- BinaxNOW is the most studied and widely available rapid antigen test in the U.S. and initially will be available at CVS Pharmacy, Walgreens and Walmart without a prescription- Abbott to manufacture tens of millions of BinaxNOW Self Tests per month and can scale capacity upward based on demand- The BinaxNOW Self Test will be sold in 2-count packs for an MSRP of $23.99, making it the most affordable over-the-counter (OTC) COVID-19 rapid test available in the U.S.
Apr 12, 2021- Abbott, Eliud Kipchoge and the NN Running Team collaborate in a partnership to track glucose levels during training and marathons- Kipchoge and NN Running Team members will wear Abbott's Libre Sense Glucose Sport Biosensor in upcoming competition at the NN Mission Marathon, the fastest way to the Tokyo Games- Built upon the company's world-leading continuous glucose monitoring technology,[i] Abbott's Libre Sense is the world's first glucose biosensor[ii] designed for athletes to help sports performance- Apr 8, 2021- New enhancements to first-of-its-kind device uniquely developed for the difficult-to-treat tricuspid valve- Next-generation therapy offers enhanced leaflet grasping feature and new clip sizes to fit each patient's complex tricuspid valve anatomy- TriClip G4 makes treatment more customizable, expanding options for physicians seeking innovative transcatheter structural heart solutions
- Apr 6, 2021- New shorter duration of dual anti-platelet therapy (DAPT) post XIENCE stent implant provides physicians with additional options to treat patients at high risk of bleeding- XIENCE is the most used drug eluting stent in the world, and European approval for shorter DAPT is supported by two studies that demonstrated safe treatment of stented patients with one-month or three-month use of DAPT- Recent data demonstrate XIENCE with short DAPT does not increase cardiac events and reduces severe bleeding, further confirming the leading safety profile of the XIENCE stent
Mar 31, 2021- FDA Emergency Use Authorization permits asymptomatic, non-prescription, over-the-counter self use for people with or without symptoms- The BinaxNOW COVID-19 Self Test is identical to the professional-use test, used since August 2020, bringing the most studied and widely used rapid antigen test to retail shelves across the country- BinaxNOW Self Test will be available nationwide and in large quantities at major food, drug and mass merchandiser retailers nationally and will be priced affordably, similar to common over-the-counter (OTC) tests- Together with vaccines, serial testing of asymptomatic people will help restore a sense of safety in everyday settings where people gather- Asymptomatic multi-test authorization also applies to BinaxNOW professional-use test- Mar 11, 2021- The Abbott Pandemic Defense Coalition is a first-of-its-kind global scientific network dedicated to the early detection of, and rapid response to, future pandemic threats- The coalition builds on Abbott's decades of leadership in virus surveillance and helps to analyze virus samples for unknown diseases and detect mutations and variants including for COVID-19- Abbott is bringing together global collaborators specializing in identification of unknown diseases, surveillance, virus sample collection, testing and sequencing- Abbott will rapidly develop tests that can be used to help identify, isolate and contain outbreaks when potential new virus threats are identified
- Mar 8, 2021- Newly FDA-approved system allows a patient to both communicate with a physician and remotely receive stimulation settings in real time regardless of location*- NeuroSphere Virtual Clinic utilizes advancements made in digital technology to optimize care through intuitive tools that enhance therapy management- Virtual clinic technology can change the treatment approach for patients who live far from necessary medical care or who are burdened by visiting the doctor in person
- Mar 5, 2021-- Abbott's Alinity™ m Resp-4-Plex assay will allow healthcare workers to test for four viruses in one test, a critically important tool as flu presents with similar symptoms-- The test helps save on much-needed testing supplies since it allows for testing for all four viruses with one swab-- Assay will run on Abbott's most advanced molecular PCR platform, the Alinity m system, which provides fast results in high volumes-- Abbott also received updated EUA for asymptomatic usage of its Alinity m SARS-CoV-2 assay
- Mar 2, 2021- Study of more than 10,000 people identifies a rare group with controlled HIV in the Democratic Republic of Congo, suggesting additional research could uncover links between natural virus suppression and future treatments- Discovery is a result of Abbott's continued virus hunting efforts, which also uncovered a new strain of HIV in 2019- Abbott's decades of work in global viral surveillance has advanced the understanding of HIV and allowed the company to quickly respond to the COVID-19 pandemic with its diagnostic tests
-
Feb 1, 2021- Support for the Easterseals Black Child Fund Will Advance Early Identification and Interventions Among Black Children to Reduce Health Disparities Often Experienced in Early Childhood
- Jan 27, 2021- Sales of $10.7 billion, including $2.4 billion of COVID-19 diagnostic testing-related sales- Sales growth of 28.7 percent; organic sales growth of 28.4 percent- GAAP diluted EPS from continuing operations growth of 103.4 percent; adjusted diluted EPS growth of 52.6 percent- Delivered more than 300 million COVID-19 diagnostics tests in fourth quarter 2020- R&D pipeline continues to be highly productive, delivering ground-breaking innovations and a steady cadence of important new products across all business areas- Issues 2021 EPS growth forecast of more than 35 percent
- Jan 26, 2021- Panbio™ COVID-19 Ag Rapid Test Device supports mass testing in congregate populations of people (mass screening) who are asymptomatic- Frequent screening of asymptomatic and symptomatic people helps restore a sense of safety at workplaces, schools, travel and recreational settings, and other places where people gather in large numbers- Test is approved for use with a patient-friendly and minimally invasive nasal swab; patients can self-administer sample collection under a healthcare professional's supervision- Panbio COVID-19 Ag delivers results in as early as 15 minutes with no instrumentation, using proven Abbott lateral flow technology- Test performance in clinical study demonstrated 93.8% sensitivity and 100.0% specificity in asymptomatic people with high viral loads- Along with the test, Abbott will offer complementary digital solutions: the NAVICA™ mobile app to allow people to display negative results for proof of testing and Sympheos™ for surveillance management to understand epidemiological trends- Since August 2020 to date, Abbott has shipped 200 million Panbio rapid antigen tests to 120 countries worldwide